Kaken Pharmaceutical Co., Ltd. (TYO:4521)

Market Cap	161.13B -11.5%
Revenue (ttm)	75.66B -18.9%
Net Income	-3.83B
EPS	-100.31
Shares Out	37.87M
PE Ratio	n/a
Forward PE	79.93
Dividend	190.00 (4.50%)
Ex-Dividend Date	Mar 30, 2026

Volume	130,100
Average Volume	143,465
Open	4,240.00
Previous Close	4,220.00
Day's Range	4,210.00 - 4,270.00
52-Week Range	3,540.00 - 4,588.00
Beta	0.09
RSI	52.66
Earnings Date	May 12, 2026

About Kaken Pharmaceutical

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surger...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1917
• Employees: 1,126
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4521

Financial Performance

In fiscal year 2025, Kaken Pharmaceutical's revenue was 94.04 billion, an increase of 30.52% compared to the previous year's 72.04 billion. Earnings were 13.95 billion, an increase of 73.77%.